Spots Global Cancer Trial Database for First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC
Official Title: Randomized, Double-blind, Multi-center Study Comparing MCC to BCG as First Line Immunotherapy in Patients With Non-muscle Invasive (Superficial) Bladder Cancer at High Risk of Recurrence or Progression
Study ID: NCT01284205
Conditions
Study Description
Brief Summary: The purpose of this study is to compare the safety and efficacy of EN3348 (MCC) versus BCG as first line treatment in patients with non-muscle invasive bladder cancer that are at high risk for recurrence or progression.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, Laguna Hills, California, United States
, Los Angeles, California, United States
, San Diego, California, United States
, Englewood, Colorado, United States
, Daytona Beach, Florida, United States
, Overland Park, Kansas, United States
, Shreveport, Louisiana, United States
, Garden City, New York, United States
, New York, New York, United States
, Pittsburgh, Pennsylvania, United States
, Myrtle Beach, South Carolina, United States
, McAllen, Texas, United States
, Salt Lake City, Utah, United States
, Norfolk, Virginia, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
